Active · per the CBE, 29 October 2026

Pharma Construct

BE0788946332

Rechtspersoon Private limited company 1 establishment

Pharma Construct is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: consultancy, property developer. Private Limited, started on 27 July 2022, 1 establishment.

Grand'Route 43, 4590 Ouffet

Behind the company: François Van Sull.

Active for

4 year, 3 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Negative equity NBB

    More debt than assets in 2 of the last 4 fiscal years.

  • Two loss years in a row NBB

    Negative result in 2024 and 2025.

  • Tight liquidity NBB

    Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Pharma Construct from Ouffet, company number BE0788946332, closed financial year 2025 with a result of € -983 after tax. For that financial year Pharma Construct recorded a gross margin of € -905 and equity of € -1,975. Compared with financial year 2024, the result moved from € -1,848 to € -983. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Caution

€ -1,975

▼ € 983 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -983

▲ 47 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53

▼ 57% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -2,975.

People and assets in 2025

Full-time equivalents estimate

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 145

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
2022202320242025Change 2024 → 2025
Gross margin € 2,340 € -1,928 € -1,771 € -905 ▲ € 866
Profit after taxes € 1,852 € -1,996 € -1,848 € -983 ▲ € 864
Equity € 2,852 € 856 € -991 € -1,975 ▼ € 983
Total debts € 1,717 € 1,254 € 1,254 € 2,400 ▲ 91%
Cash € 4,267 € 1,794 € 125 € 53 ▼ 57%
Retained profit € 1,852 € -144 € -1,991 € -2,975 ▼ € 983
Balance sheet total € 4,569 € 2,111 € 263 € 425 ▲ 62%

Key figures of Pharma Construct, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharma Construct?

What happened at Pharma Construct in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 983. Source: NBB ↗
  • New establishment in Ouffet. KBO
  • François Van Sull became a director. NBB
  • Start of the company according to the CBE. KBO

In short

From € 1,852 profit in 2022 to € 983 loss in 2025.

Paid € 463 in corporate taxes since 2022.

Best year ever: 2022, with € 1,852 profit.

Original PDFs at the National Bank ↗

Management

François Van Sull
Pharma Construct
PHARMACIE PIERRE WAGNER
Pharmacie BAECKEN
PHARMACIE D'HELECINE
+3

Behind Pharma Construct is François Van Sull. François Van Sull is also behind PHARMACIE PIERRE WAGNER, Pharmacie BAECKEN, PHARMACIE D'HELECINE, SOPHARMA MANAGEMENT and FVS Management.

Directors

According to the 2025 annual accounts

François Van Sull

Director

Also active at: PHARMACIE PIERRE WAGNER, Pharmacie BAECKEN, PHARMACIE D'HELECINE, SOPHARMA MANAGEMENT, FVS Management, PHARMACIE BODEN

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Grand'Route 43

4590 Ouffet

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

FVS Management same network

€ 401,477 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0788.946.332
VAT number
BE 0788.946.332
Registered office
Grand'Route 43, 4590 Ouffet
Names & denominations
Pharma Construct
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
27 July 2022
Peppol
Active · Active since 8 Aug 2022
Activities · NACE

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Ontwikkeling van niet-residentiële bouwprojecten

Ontwikkeling van residentiële bouwprojecten

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What does Pharma Construct do?
Pharma Construct is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: consultancy, property developer. Private Limited, started on 27 July 2022, 1 establishment.
What is the address of Pharma Construct?
The registered office of Pharma Construct is located at Grand'Route 43, 4590 Ouffet.
Is Pharma Construct still active?
Yes. According to the CBE (29 October 2026) Pharma Construct is active, legal situation “Normale toestand”, started on 27 July 2022.
Is Pharma Construct registered on Peppol?
Yes, Pharma Construct is registered on the Peppol network with ID 0208:0788946332.
What is the enterprise number of Pharma Construct?
The enterprise number of Pharma Construct is BE0788946332.
When was Pharma Construct founded?
Pharma Construct was founded on 27 July 2022.